EADV 2025 Coverage: Incyte’s Povorcitinib Improves Moderate-to-severe HS at Week 24
Povorcitinib, Incyte’s oral Janus kinase (JAK) inhibitor, produced clinically meaningful and statistically significant improvements for adults with active moderate-to-severe hidradenitis suppurativa (HS) through Week 24, according to new results from the Phase 3 STOP-HS clinical trial program that were presented at the European Association of Dermatology and Venereology (EADV) 2025 Congress in Paris, France.